炎症性细胞因子和过敏性鼻炎的风险:孟德尔的随机化研究
Xu Zhang1, Peng Wang2, Qiuling Dang3
1Dalian Medical University, Dalian 116000, China.
Cytokine
|February 19, 2024
概括
这项研究表明,较高水平的介素-18 (IL-18) 和巨细胞炎症蛋白-1α (MIP-1α) 可能会增加过敏性鼻炎 (AR) 风险,而 TRAIL 可能会降低风险. 需要进一步的研究来证实这些关于AR的发现.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
- 流行病学 流行病学
背景情况:
- 慢性炎症与过敏性鼻炎 (AR) 有关.
- 特定循环细胞因子和AR之间的因果关系尚不清楚.
- 区分原因和后果对于理解AR病原体至关重要.
研究的目的:
- 研究26种循环炎性细胞因子对AR风险的因果作用.
- 为了确定对更高细胞因子水平的遗传倾向是否影响AR发生.
- 应用门德尔的随机化 (MR) 来评估这些关系.
主要方法:
- 进行了两样本的门德尔随机化 (MR) 分析.
- 逆方差加权 (IVW) 方法是主要的分析方法.
- 敏感性分析包括中位数,加权中位数,处罚加权中位数和MR-Egger回归.
主要成果:
- 有关证据表明,较高的IL-18和MIP-1α水平与AR风险增加有关.
- 较高的TRAIL水平与AR的风险降低有关.
- 仅TRAIL和AR风险之间的关联在Bonferroni调整后仍然显著.
结论:
- 基因预测较高的IL-18和MIP-1α水平可能会增加AR风险.
- 基因预测较高的TRAIL水平似乎可以降低AR风险.
- 目前的证据并不表明其他炎症性细胞因子与AR风险有关;需要进一步的研究.
相关概念视频
Allergic Reactions
27.4K
Overview
27.4K
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Drugs Used in Lower Respiratory Disorders: Overview
442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442
Asthma: Pathogenesis and Management
398
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
398
Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K


